Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
about
Desensitization for solid organ and hematopoietic stem cell transplantationModern approaches to incompatible kidney transplantationTreatment options and strategies for antibody mediated rejection after renal transplantationB cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapyIncompatible live-donor kidney transplantation in the United States: results of a national surveyDesensitization: Overcoming the Immunologic Barriers to TransplantationTherapeutic apheresis before and after kidney transplantation.The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends.Promising recent data on ABO incompatible liver transplantation: restrictions may apply.Intravenous immunoglobulin as clinical immune-modulating therapy.Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.Preexisting donor-specific HLA antibodies predict outcome in kidney transplantationDesensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation.Diagnosis and management of antibody-mediated rejection: current status and novel approaches.IVIg treatment reduces catalytic antibody titers of renal transplanted patientsPreformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipientsComplete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic OpportunityUtility of HLA Antibody Testing in Kidney Transplantation.Intravenous immunoglobulin for antibody-mediated keratolimbal allograft rejectionIntravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs.Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidatesA case of desensitization, transplantation, and allograft dysfunction.Humoral rejection of organ allografts.The patient: Emerging clinical applications of intravenous immunoglobulin.Transplantation across previously incompatible immunological barriers.Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients.Pediatric renal transplantation in a highly sensitised child-8 years on.Desensitization strategies enabling successful renal transplantation in highly sensitized patients.The HLA system: genetics, immunology, clinical testing, and clinical implications.New treatments for acute humoral rejection of kidney allografts.Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.Successful renal transplantation with desensitization in highly sensitized patients: a single center experience.Early and Sustained Reduction in Donor-Specific Antibodies in Desensitized Living Donor Kidney Transplant Recipients: A 3-Year Prospective Study.The role of positive flow cytometry crossmatch in late renal allograft lossChallenges with sensitized recipients in pediatric heart transplantation.Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine.Advances in diagnosing and managing antibody-mediated rejection.Antibody-Mediated Rejection: A Review.
P2860
Q26863564-85495F98-95CD-4617-AEE3-3EBC9AD3C715Q27010224-E5BDEA9B-3FC2-4D0C-B05B-DE0620B7B665Q27021397-BFEDEA31-D49D-4E94-AC6D-F0446171E7CBQ28563989-C5EA0BC1-1A07-4254-B47A-F5F0F4495C55Q28741418-73F59C7A-F5D9-46B3-8366-B64560177CDEQ30397952-631FBC55-56EC-4D2E-8073-93948EC83FC6Q30454250-395429D8-CFF1-431B-870B-F92F722072EBQ30455087-B9B20050-F2BC-44CF-8491-CF7BE8B7BBC4Q31117692-F29705ED-6BD1-4E1C-A6C5-3EE303CDE0ABQ33420267-CE085441-D522-4F61-8E36-E9E785E510E0Q33560520-F8300B94-C5C1-4E97-BDCD-9A03D3C639E7Q33842250-42A06802-7347-49E8-AA0F-7431C94CD90DQ34124202-65BB87A5-2556-4845-8B55-9F568380E7D0Q34767262-AA9100BA-1E7D-43F0-ACEB-52C382CC0BB3Q34841849-8622864A-6A70-4C10-B748-7DD3C343532DQ34962680-F106576F-814A-48C1-AA88-AC984E90FC91Q35616055-F17431CB-E1E0-4C7D-8D70-20503E5399ACQ35692718-1219D118-F48A-4159-AFE5-D2F07EA732EFQ35790601-E0DFEAD7-A424-4758-B3DB-F386515F3217Q35808401-D0B7F747-149F-40B3-9C52-965AC1586D52Q35955607-685343B6-C13B-4B26-882C-1957D87AE1C4Q36053023-3685231E-C10F-4028-B42B-9DF03D5EBB3BQ36063312-E6C749AC-6D01-41BD-BE28-7A7DBA65C4CAQ36280431-AA9B9C53-398B-4529-9E32-B5BAF58761BEQ36288350-9155C4CB-D734-4581-995F-B52F2659127CQ36379447-A403F2F8-1473-408A-87C3-CBF7D263A5BAQ36392146-65A5910E-E62D-4E11-9483-F30FFF16750EQ36422175-2AA2A371-68D1-4672-A639-EF57E737D9EFQ36652013-0C018B91-0933-4846-A773-1F7B7E0A2938Q36746594-AD4EC90C-518B-4E9F-B438-99AB7C6D8742Q36802609-2023FE73-BB0F-4406-8F73-B4E7B8F8CD16Q36827985-5FCF6215-E9FE-4BCA-8535-F4DE75F49C97Q37078119-F8095097-092D-4FF9-8BC3-C7B3830702B1Q37097768-5B9BF627-63D8-48A4-9605-E613FCE59635Q37311402-6A322C32-9643-460C-92CF-9B0A7502652EQ37446864-A3A903E0-0658-4EEF-B213-EFD90786F17BQ37626123-F8836142-A64A-466E-9236-CB1891E6BEB5Q37641415-32986FBF-0F04-4574-8C3A-82369F3928CFQ37676032-EF04A5B3-E971-4E11-88EC-2A7D67CAF31AQ37698860-A57ED1FE-1150-40D1-92C8-E4E4F89450AD
P2860
Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@ast
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@en
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@nl
type
label
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@ast
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@en
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@nl
prefLabel
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@ast
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@en
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@nl
P2093
P1476
Evaluation of intravenous immu ...... report of the NIH IG02 trial.
@en
P2093
Connie Davis
Dawn Milliner
Deborah Adey
Dolly Tyan
Don Stablein
Gaetano Ciancio
Jimmy Light
Matthew McIntosh
Mieko Toyoda
P304
P356
10.1097/01.ASN.0000145878.92906.9F
P577
2004-12-01T00:00:00Z